These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22696079)

  • 41. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
    Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Vachiery JL; Grünig E; Oudiz RJ; Vonk-Noordegraaf A; White RJ; Blair C; Gillies H; Miller KL; Harris JH; Langley J; Rubin LJ;
    N Engl J Med; 2015 Aug; 373(9):834-44. PubMed ID: 26308684
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Galiè N; Ghofrani HA; Torbicki A; Barst RJ; Rubin LJ; Badesch D; Fleming T; Parpia T; Burgess G; Branzi A; Grimminger F; Kurzyna M; Simonneau G;
    N Engl J Med; 2005 Nov; 353(20):2148-57. PubMed ID: 16291984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes.
    Zheng Y; Yang T; Chen G; Hu E; Gu Q; Xiong C
    Eur J Clin Pharmacol; 2014 Jan; 70(1):13-21. PubMed ID: 24026627
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
    Rhee RL; Gabler NB; Praestgaard A; Merkel PA; Kawut SM
    Arthritis Rheumatol; 2015 Sep; 67(9):2457-65. PubMed ID: 26016953
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Six-minute walk distance in patients with severe end-stage COPD: association with survival after inpatient pulmonary rehabilitation.
    Enfield K; Gammon S; Floyd J; Falt C; Patrie J; Platts-Mills TA; Truwit JD; Shim YM
    J Cardiopulm Rehabil Prev; 2010; 30(3):195-202. PubMed ID: 20040883
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A pulmonary hypertension gas exchange severity (PH-GXS) score to assist with the assessment and monitoring of pulmonary arterial hypertension.
    Woods PR; Taylor BJ; Frantz RP; Johnson BD
    Am J Cardiol; 2012 Apr; 109(7):1066-72. PubMed ID: 22245407
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Introduction. Pulmonary arterial hypertension].
    Simonneau G
    Presse Med; 2010 Jun; 39 Suppl 1():1S1-2. PubMed ID: 20732612
    [No Abstract]   [Full Text] [Related]  

  • 49. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study.
    Peacock AJ; Crawley S; McLure L; Blyth KG; Vizza CD; Poscia R; Francone M; Iacucci I; Olschewski H; Kovacs G; Vonk Noordegraaf A; Marcus JT; van de Veerdonk MC; Oosterveer FP
    Circ Cardiovasc Imaging; 2014 Jan; 7(1):107-14. PubMed ID: 24173272
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.
    Safdar Z
    Vasc Health Risk Manag; 2011; 7():119-24. PubMed ID: 21468170
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survival after pulmonary rehabilitation in patients with COPD: impact of functional exercise capacity and its changes.
    Camillo CA; Langer D; Osadnik CR; Pancini L; Demeyer H; Burtin C; Gosselink R; Decramer M; Janssens W; Troosters T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2671-2679. PubMed ID: 27822029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pulmonary hypertension: current diagnosis and treatment.
    Rosenkranz S
    Clin Res Cardiol; 2007 Aug; 96(8):527-41. PubMed ID: 17534570
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension.
    Wirostko BM; Tressler C; Hwang LJ; Burgess G; Laties AM
    BMJ; 2012 Feb; 344():e554. PubMed ID: 22354598
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Specific drugs for the treatment of pulmonary arterial hypertension - current status].
    Stähler G
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S183-6. PubMed ID: 18814092
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.
    Galiè N; Humbert M; Vachiéry JL; Vizza CD; Kneussl M; Manes A; Sitbon O; Torbicki A; Delcroix M; Naeije R; Hoeper M; Chaouat A; Morand S; Besse B; Simonneau G;
    J Am Coll Cardiol; 2002 May; 39(9):1496-502. PubMed ID: 11985913
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of dyspnea in advanced pulmonary arterial hypertension.
    Sajkov D; Petrovsky N; Palange P
    Curr Opin Support Palliat Care; 2010 Jun; 4(2):76-84. PubMed ID: 20407377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
    Galiè N; Rubin Lj; Hoeper M; Jansa P; Al-Hiti H; Meyer G; Chiossi E; Kusic-Pajic A; Simonneau G
    Lancet; 2008 Jun; 371(9630):2093-100. PubMed ID: 18572079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selexipag for the Treatment of Pulmonary Arterial Hypertension.
    Sitbon O; Channick R; Chin KM; Frey A; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; Preiss R; Rubin LJ; Di Scala L; Tapson V; Adzerikho I; Liu J; Moiseeva O; Zeng X; Simonneau G; McLaughlin VV;
    N Engl J Med; 2015 Dec; 373(26):2522-33. PubMed ID: 26699168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.